Morgan Stanley Increases Humana (HUM) Price Target to $418.00

Share on StockTwits

Humana (NYSE:HUM) had its target price raised by stock analysts at Morgan Stanley from $400.00 to $418.00 in a note issued to investors on Thursday. The firm currently has a “buy” rating on the insurance provider’s stock. Morgan Stanley’s price target would indicate a potential upside of 23.32% from the stock’s previous close.

HUM has been the topic of several other reports. MED lifted their price target on Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Jaffray Companies lifted their price objective on Humana from $355.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 24th. Bank of America lifted their price objective on Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Royal Bank of Canada reissued a “hold” rating and set a $318.00 price objective on shares of Humana in a report on Thursday, August 2nd. Finally, SunTrust Banks lifted their price objective on Humana to $380.00 and gave the stock a “hold” rating in a report on Wednesday, September 19th. Seven equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $352.30.

Shares of NYSE HUM opened at $338.95 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $48.77 billion, a price-to-earnings ratio of 25.36, a price-to-earnings-growth ratio of 1.73 and a beta of 1.03. Humana has a 12 month low of $231.90 and a 12 month high of $355.88.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion for the quarter, compared to the consensus estimate of $13.97 billion. Humana had a return on equity of 19.36% and a net margin of 2.70%. During the same period in the previous year, the business posted $3.39 EPS. On average, research analysts forecast that Humana will post 14.44 earnings per share for the current fiscal year.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now directly owns 14,289 shares in the company, valued at approximately $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in Humana by 1.4% in the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after buying an additional 167,283 shares in the last quarter. BlackRock Inc. boosted its stake in Humana by 1.2% in the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after buying an additional 140,731 shares in the last quarter. Northern Trust Corp boosted its stake in Humana by 1.2% in the 2nd quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock valued at $502,164,000 after buying an additional 20,480 shares in the last quarter. Acadian Asset Management LLC raised its position in Humana by 7.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Humana by 4.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock valued at $272,199,000 after purchasing an additional 35,845 shares during the last quarter. 92.62% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Dividend Aristocrat Index

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.